Tag: Biosimilar cost

Biosimilars generally cost 15% to 45% less than the originator biologic, making it highly likely that **is Truxima cheaper than rituximab?** Yes, it is, and this article explains why these cost savings are so crucial for patients and the healthcare system. Approved in 2018 as the first rituximab biosimilar, Truxima (rituximab-abbs) was launched with a significant discount compared to the brand-name Rituxan.

As of late 2022, when it first launched, Cimerli's initial list price was up to 30% lower than its reference product, Lucentis. Understanding **how much does Cimerli cost?** involves examining list prices, insurance coverage, and manufacturer assistance programs, which can significantly alter a patient’s final out-of-pocket expense.